The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

Area of Science:

• Biotechnology
• Drug Delivery Systems
• Molecular Medicine

Background:

• In vivo expression of exogenous mRNA was first achieved via direct intramuscular injection in mice.
• Lipid nanoparticles (LNPs) are the current standard for therapeutic nucleic acid delivery, comprising cholesterol, helper lipids, PEGylated lipids, and ionizable lipids.
• LNPs primarily accumulate in the liver after intravenous administration, with varying degrees observed after intramuscular and subcutaneous routes.

Purpose of the Study:

• To review current strategies for developing next-generation tissue-targeted lipid nanoparticle (LNP) constructs.
• To address the limitations of current LNP delivery, which is largely confined to the liver.
• To explore the potential of non-hepatic LNP targeting for various diseases.

Main Methods:

• Review of current literature on lipid nanoparticle (LNP) development.
• Analysis of strategies for achieving tissue-specific LNP targeting.
• Examination of LNP composition and its impact on biodistribution.

Main Results:

• Lipid nanoparticles (LNPs) show potential for delivering nucleic acids to hepatocytes.
• Significant therapeutic opportunities exist for non-hepatic LNP targeting in oncology, neurology, cardiovascular, and infectious diseases.
• Ongoing research focuses on engineering LNPs for precise tissue and cell population targeting.

Conclusions:

• Targeted delivery of nucleic acids using advanced lipid nanoparticles (LNPs) is crucial for expanding therapeutic applications.
• Overcoming the hepatic tropism of current LNPs is key to treating a wider range of diseases.
• The development of next-generation tissue-targeted LNPs holds promise for future precision medicine.